Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis
Sponsor: RVL Pharmaceuticals, Inc.
Listed as NCT01848041, this PHASE1/PHASE2 trial focuses on Blepharoptosis and remains completed. Sponsored by RVL Pharmaceuticals, Inc., it has been updated 11 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Completed PHASE1_PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — May 2020 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- RVL Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .